Gregory Vidal, MD, PhD, on Treating Patients with HER2+ Breast Cancer During COVID-19

October 16, 2020

The breast cancer expert discussed the changes he has made in treating this patient population as a result of the COVID-19 pandemic.

Due to the coronavirus disease 2019 (COVID-19) pandemic, oncologists have had to modify the ways they care and provide treatment for their patients with breast cancer, especially those with HER2-positive breast cancer.

Some of the changes implemented by oncologists have included telehealth visits as opposed to in-clinic visits, as well as delays in elective surgeries.

In an interview with CancerNetwork®, Gregory Vidal, MD, PhD, a medical oncologist at West Cancer Center and Research Institute and associate professor in the department of hematology/oncology at The University of Tennessee Health Science Center in Memphis, spoke about treating patients with HER2-positive breast cancer in the midst of the pandemic and the changes that his practice has implemented as a result.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.